Showing results (11-20 of 54) with videos related to
Sort By:
Pageof 6
Nature Medicine|November 22, 2011
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress responseBogdan Mateescu, Luciana Batista, Melissa Cardon, et al.Plos One|August 27, 2013
New blocking antibodies impede adhesion, migration and survival of ovarian cancer cells, highlighting MFGE8 as a potential therapeutic target of human ovarian carcinomaLorenzo Tibaldi, Shirley Leyman, André Nicolas, et al.Oncoimmunology|September 14, 2016
No evidence for TSLP pathway activity in human breast cancerCristina Ghirelli, Benjamin Sadacca, Fabien Reyal, et al.The Journal of Pathology|January 25, 2023
Progression-associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesisJacqueline Fontugne, Jennifer Wong, Luc Cabel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2016
Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against CancerHamza Mameri, Ivan Bièche, Didier Meseure, et al.Molecular Oncology|July 5, 2014
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic targetNabil Amirouchene-Angelozzi, Fariba Nemati, David Gentien, et al.Developmental Cell|December 27, 2024
TFEB triggers a matrix degradation and invasion program in triple-negative breast cancer cells upon mTORC1 repressionDavid Remy, Sandra Antoine-Bally, Sophie de Toqueville, et al.Cancers|August 27, 2021
CENP-A Subnuclear Localization Pattern as Marker Predicting Curability by Chemoradiation Therapy for Locally Advanced Head and Neck Cancer PatientsPierre Verrelle, Didier Meseure, Frédérique Berger, et al.BMC Cancer|May 25, 2010
A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancerJean-Philippe Meyniel, Paul H Cottu, Charles Decraene, et al.Journal of Hematology & Oncology|September 9, 2021
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breastIvan Bièche, Florence Coussy, Rania El-Botty, et al.Pageof 6